Celyad SA (CYAD) Sets New 12-Month Low at $20.90
Shares of Celyad SA (NASDAQ:CYAD) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $20.90 and last traded at $21.05, with a volume of 10,370 shares. The stock had previously closed at $21.45.
A number of brokerages recently issued reports on CYAD. Zacks Investment Research raised Celyad SA from a “hold” rating to a “buy” rating and set a $56.00 price objective for the company in a research report on Wednesday, May 25th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $95.00 target price on shares of Celyad SA in a research report on Tuesday, June 7th.
The stock’s market capitalization is $195.57 million. The firm’s 50-day moving average is $24.22 and its 200-day moving average is $38.08.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/celyad-sa-cyad-sets-new-12-month-low-at-20-90.html
A hedge fund recently raised its stake in Celyad SA stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Celyad SA (NASDAQ:CYAD) by 24.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,161 shares of the company’s stock after buying an additional 3,426 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.18% of Celyad SA worth $429,000 as of its most recent SEC filing.
About Celyad SA
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Receive News & Ratings for Celyad SA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celyad SA and related companies with MarketBeat.com’s FREE daily email newsletter.